University of Michigan Roger Cancer Center is probably the most experienced site in histotripsy that was approved by the FDA since late 2023 for non-invasive ablation of liver tumors, including metastasis from pancreatic cancer. It requires patients have oligometastatic disease and that is no more than 5 tumors up to a size of 5 cm.

There are two key MD’s involved with the development of the procedure, clinical trial and studies. They are Clifford Cho, MD and Mishal Mendiratta-Lala, MD. One’s oncologist is best to make contact with either of these two physicians. Have the oncologist submit a referral to the Rogel Cancer Center via their Cancer AnswerLine or if an oncologist is calling, look on the aRogel,Cancer site for M-Line contact info.

Next request a multidisciplinary liver tumor clinic. This likely can be done virtually with the requestor. Mention histotripsy specifically for pancreatic metastatic disease. The requestor should specifically request coordination with Drs. Cho, Mendiratta-Layla and Dr.Xu who is one of the PhD developers of the technology.. This will likely get consideration for advanced options.

Phone for patients: 800-865-1125
E-Mail: CancerAnswerLine@med.umich.edu
Hours: Mon—Fri, 8 am- 4:30 pm ET